BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLC
Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented at the International Association ...
Sep 9, 2024
0
0